Genitourinary malignancies including prostate cancer, bladder cancer, renal cell carcinoma and urothelial cancer remain a challenge in the field of oncology due to limited treatment options. There have been development in the field of treatment over the years including a novel approach using Antibody-drug conjugates (ADCs) which represents a promising advancing treatment alternative which combines the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Sacituzumab govitecan targeting trop-2 and enfortumab vedotin directed against nectin-4 have recently been approved for the treatment of urothelial carcinoma. However, new agents will add to the treatment armamentarium and address targets such as Her-2 and tissue factor. Not only new therapeutic areas of application but also the management of adverse events need to be further explored.
The goal of this Research Topic is to generate a discussion on the impact of antibody-drug conjugates in genitourinary cancers. We invite authors to submit preclinical and translational data helping to identify new targets or areas for ADC development, biomarker research that inform treatment with ADCs that are currently improved as well as clinical data including real world evidence and toxicity management.
We welcome Original Research, Systematic Reviews, Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Genitourinary malignancies including prostate cancer, bladder cancer, renal cell carcinoma and urothelial cancer remain a challenge in the field of oncology due to limited treatment options. There have been development in the field of treatment over the years including a novel approach using Antibody-drug conjugates (ADCs) which represents a promising advancing treatment alternative which combines the specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. Sacituzumab govitecan targeting trop-2 and enfortumab vedotin directed against nectin-4 have recently been approved for the treatment of urothelial carcinoma. However, new agents will add to the treatment armamentarium and address targets such as Her-2 and tissue factor. Not only new therapeutic areas of application but also the management of adverse events need to be further explored.
The goal of this Research Topic is to generate a discussion on the impact of antibody-drug conjugates in genitourinary cancers. We invite authors to submit preclinical and translational data helping to identify new targets or areas for ADC development, biomarker research that inform treatment with ADCs that are currently improved as well as clinical data including real world evidence and toxicity management.
We welcome Original Research, Systematic Reviews, Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
